After oral administration, it is quickly and completely absorbed from the gastrointestinal tract. Time to reach the maximum concentration in plasma (TFROMmax) is 2.6 hours after administration. The average plasma concentration in healthy subjects after single oral administration at a dose of 60 mg - 209 ng / ml, the equilibrium concentration (Css) after repeated administration - 286 ng / ml. The average value of the maximum concentration (Cmax) after taking 180 mg - approximately 494 ng / ml, after taking 120 mg - 289 ng / ml, after taking 60 mg - 131 ng / ml.
Pharmacokinetics is practically linear with daily intake in the dose range of 60-180 mg. Connection with plasma proteins - 60-70% (mainly with albumin and alpha-1-acid glycoprotein). It does not penetrate the blood-brain barrier (GEB), it is secreted into breast milk.
The half-life (T1/2) after repeated admission - 14.4 hours, the area under the pharmacokinetic curve of the concentration versus time (AUC) - 1521 μg / l / h, clearance - 3,4 ml / min / kg.
In patients with moderate (creatinine clearance (CC) 41-80 ml / min) and severe (11-40 ml / min) renal failure T1/2 increases by 59 and 72%, respectively; in patients on hemodialysis, T1/2 increases by 31%. It is exposed (5% of the dose) to partial extrahepatic metabolism.
Mostly (80%) is excreted with bile, 10% with unchanged kidneys.
Patients 65 years of age or older T1/2 does not change, the concentration in the blood increases, but this does not affect the tolerability of the drug. Against the background of renal dysfunction and hemodialysis CmOh increases and T1/2 lengthens.
The pharmacokinetic parameters of fexofenadine in patients with liver diseases vary slightly.